Abediterol (Almirall/Forest) superior to indacaterol in Phase IIa trial for COPD

In the Phase IIa, single-dose, study change from baseline in trough FEV1 following a single dose administration of a range of abediterol from Almirall/Forest Labs. doses below 10µg once daily, showed a statistically significant improvement versus placebo (p<0.001 for all abediterol doses) and, also, versus indacaterol 150µg (p<0.001 for abediterol doses of 2.5, 5 and 10µg. Abediterol once-daily in fixed dose combination with an inhaled corticosteroid is now ready to move into Phase IIb clinical development worldwide for asthma and COPD. .